Non-alcoholic fatty liver disease concerns with glucokinase activators
We read with interest the Article in The Lancet Diabetes and Endocrinology by Dalong Zhu and colleagues, in which dorzagliatin, a dual-acting, allosteric glucokinase activator, showed a beneficial effect on glycaemic control in a phase 2 trial. Although the introduction of a new class of glucose-low...
| Main Authors: | , |
|---|---|
| Format: | Journal article |
| Published: |
Elsevier
2018
|
| _version_ | 1797081177015713792 |
|---|---|
| author | Hodson, L Brouwers, M |
| author_facet | Hodson, L Brouwers, M |
| author_sort | Hodson, L |
| collection | OXFORD |
| description | We read with interest the Article in The Lancet Diabetes and Endocrinology by Dalong Zhu and colleagues, in which dorzagliatin, a dual-acting, allosteric glucokinase activator, showed a beneficial effect on glycaemic control in a phase 2 trial. Although the introduction of a new class of glucose-lowering drugs with a different mode of action is always welcome, particularly in this era of precision medicine, it is important to question the metabolic consequences of the dorzagliatin-induced reduction in plasma glucose. |
| first_indexed | 2024-03-07T01:10:51Z |
| format | Journal article |
| id | oxford-uuid:8cf44540-3c85-412c-a376-34331c5f70e4 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T01:10:51Z |
| publishDate | 2018 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:8cf44540-3c85-412c-a376-34331c5f70e42022-03-26T22:48:01ZNon-alcoholic fatty liver disease concerns with glucokinase activatorsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8cf44540-3c85-412c-a376-34331c5f70e4Symplectic Elements at OxfordElsevier2018Hodson, LBrouwers, MWe read with interest the Article in The Lancet Diabetes and Endocrinology by Dalong Zhu and colleagues, in which dorzagliatin, a dual-acting, allosteric glucokinase activator, showed a beneficial effect on glycaemic control in a phase 2 trial. Although the introduction of a new class of glucose-lowering drugs with a different mode of action is always welcome, particularly in this era of precision medicine, it is important to question the metabolic consequences of the dorzagliatin-induced reduction in plasma glucose. |
| spellingShingle | Hodson, L Brouwers, M Non-alcoholic fatty liver disease concerns with glucokinase activators |
| title | Non-alcoholic fatty liver disease concerns with glucokinase activators |
| title_full | Non-alcoholic fatty liver disease concerns with glucokinase activators |
| title_fullStr | Non-alcoholic fatty liver disease concerns with glucokinase activators |
| title_full_unstemmed | Non-alcoholic fatty liver disease concerns with glucokinase activators |
| title_short | Non-alcoholic fatty liver disease concerns with glucokinase activators |
| title_sort | non alcoholic fatty liver disease concerns with glucokinase activators |
| work_keys_str_mv | AT hodsonl nonalcoholicfattyliverdiseaseconcernswithglucokinaseactivators AT brouwersm nonalcoholicfattyliverdiseaseconcernswithglucokinaseactivators |